Phase 2 N=5 Treatment

The Effect of Bevacizumab (Avastin) on Pterygium

Pterygium

Bottom Line

View on ClinicalTrials.gov: NCT00592176 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Jun 2012

Primary outcome: Primary: The Area the Pterygium Enlarged or Regressed as Measured From the Limbus Before and After Subconjunctival Bevacizumab Injection. — 5.75 area in millimeters squared — p=0.83

Study Design & Population

Study type: Interventional
Phase: Phase 2
Interventions: local injection of bevacizumab (Drug)
Age: Adult, Older Adult · 19+ yrs
Sex: All
Sponsor: University of Alabama at Birmingham
Primary completion: Mar 2010

Outcome Measures

Outcome	Result	p-value
PRIMARY The Area the Pterygium Enlarged or Regressed as Measured From the Limbus Before and After Subconjunctival Bevacizumab Injection.	5.75	0.83
SECONDARY Number of Patients Having Surgical Removal of Pterygium.	—	—

Summary

The purpose of this study is to determine whether local injection of bevacizumab might halt and or cause regression of pterygium growth. This may enable earlier treatment and prevention of pterygium growth into the patient's line of sight thereby limiting the need for surgery and improving quality of life for patients with pterygia.

Eligibility Criteria

Inclusion Criteria

19 years of age and older
Diagnosis of pterygia
healthy enough to make scheduled follow-up visits

Exclusion Criteria

Women of childbearing potential and males who plan to father a child during their participation in the study will be excluded from the study.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00592176). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.